ReviewCurrent opinion in pulmonary medicine2010
Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.
Review in Current opinion in pulmonary medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 107 citations in OpenAlex.
- Invasive aspergillosis in autoimmune inflammatory rheumatic diseases: epidemiology, risk factors, diagnosis, management and challenges.Annals of medicine · 2026Review
- Laboratory Diagnostics of Aspergillosis: Present State and Future Directions.Journal of fungi (Basel, Switzerland) · 2026Review
- Oxidoreductase geneMicrobiology spectrum · 2026Article
- Loss of pulmonary tissue protection and neutrophil microbicidal defects promote severeInfection and immunity · 2025Article
- Clinicomycological Study of the Spectrum of Pulmonary Aspergillosis at a Tertiary Care Hospital in Central India.Cureus · 2024Article
- Role of theJournal of fungi (Basel, Switzerland) · 2024Article
- Article
- Cervico-Dorsal Intramedullary Spinal Cord Abscess withMedicina (Kaunas, Lithuania) · 2023Article
- Invasive Aspergillus outbreak in inhalation injury: a case presentation and literature review.BMC infectious diseases · 2022Review
- Imaging Approach to Pulmonary Infections in the Immunocompromised Patient.The Indian journal of radiology & imaging · 2022Review
- Coinfection byCase reports in medicine · 2022Article
- Factors affecting survival after anatomical lung resection in pulmonary aspergilloma: Our 10-year single institution experience.Turk gogus kalp damar cerrahisi dergisi · 2022Article
- Native Valve Aspergillus Endocarditis in a Non-Neutropenic Immunocompromised Patient on Anti-TNF α Blockers Therapy.Cureus · 2021Article
- Determining Aspergillus fumigatus transcription factor expression and function during invasion of the mammalian lung.PLoS pathogens · 2021Article
- Article
- Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist.Journal of fungi (Basel, Switzerland) · 2020Review
- Article
- The Transcriptional Regulator HbxA Governs Development, Secondary Metabolism, and Virulence in Aspergillus fumigatus.Applied and environmental microbiology · 2020Article
- Disseminated cerebral aspergillosis complicated by thrombotic microangiopathy.Medical mycology case reports · 2019Article
- Non-culture based assays for the detection of fungal pathogens.Journal de mycologie medicale · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewWhen functioning properly, the immune system recognizes inhaled fungi and controls their growth, while avoiding injurious inflammation and allergy. 'Aspergillosis' represents a spectrum of clinical diseases resulting from impaired or excessive immune responses. Invasive aspergillosis is principally disease of severely immunocompromised patients, whereas allergic forms of aspergillosis result from an excessive inflammatory response to hyphae colonizing the sinopulmonary tract. We will review insights gained in host defense against Aspergillus species and the immunopathogenesis of Aspergillus-related diseases as well as important advances made in fungal diagnostics and antifungal therapy. RECENT
findingsImportant advances have been made in diagnosis of invasive aspergillosis and in antifungal agents. Voriconazole was superior to amphotericin B deoxycholate as primary therapy for invasive aspergillosis. There is significant interest in combination antifungal therapy for invasive aspergillosis. Fungal genomics offers a powerful opportunity to gain knowledge about fungal virulence factors that can be targets for drug development. In addition, new insights have been gained regarding host defense against Aspergillus species that may be exploited therapeutically. SUMMARY: We have gained substantial knowledge regarding how the immune system recognizes inhaled fungi and calibrates the inflammatory response. There has also been substantial progress in tools to diagnose aspergillosis and in antifungal therapeutics. Future progress will likely involve the development of more refined diagnostic tools, new classes of antifungal agents, and greater knowledge of pathogen and host factors that predispose to aspergillosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.